Saturday 17 October 2026 Export VRDN’s income statement to Excel — free account

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024. In the quarter to June 2026, revenue grew 278.7%, EPS fell 5.00%, free cash flow fell 41.4% and total debt rose 1,064.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

19.03 0.53 −2.71%

Follow VRDN

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −4.1×
Dividend yield: —
F-score: 3/9
Altman Z: 6.69
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 20.00

Total sells 0.42

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	1	—	—

Insider Ownership 1.41%

Capital & Financial Ratios $m

Market Cap 2,220.00

Revenue 71.13

Net Income (386.97)

Free Cash Flow (335.04)

Net Debt (739.37)

Current Ratio 16.95

Debt/Equity 0.37

P/E ratio 0.00

Fwd P/E (4.05)

P/S ratio 28.86

P/B ratio 3.64

Past 5Y EPS Growth —

This Y EPS Growth (18.26%)

Next Y EPS Growth 34.37%

Next Y revenue growth (57.60%)

Next 5Y EPS Growth 57.67%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 41.61%

10-year low 10-year high

P/B against its own 10 years 62.26%

10-year low 10-year high

EV/Sales against its own 10 years 38.61%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	477	718	875	982
Receivables	—	—	—	75
Inventory	—	—	—	—
Other	0	—	—	—
	486	738	894	1,081

	2023	2024	2025	Q'26
Payables	2	2	9	9
ST’ Debt	—	—	—	—
Other	—	—	—	—
	27	48	71	64

Compound Annual Growth %

	10y	5y	3y
Sales	39.50%	132.18%	241.95%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	52.80%	43.17%	22.27%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	71	0	71
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	1	0	2
’21	1	1	0	0	3
’20	1	0	—	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(120)	(105)	—	—	—
’25	(93)	(75)	(85)	(24)	(276)
’24	(45)	(46)	(68)	(73)	(232)
’23	(62)	(45)	(39)	(38)	(184)
’22	(21)	(18)	(21)	(34)	(94)
’21	(12)	(15)	(12)	(17)	(55)
’20	(8)	(7)	(5)	(9)	(30)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(120)	(107)	—	—	—
’25	(93)	(75)	(85)	(24)	(277)
’24	(45)	(46)	(68)	(73)	(233)
’23	(62)	(46)	(39)	(38)	(185)
’22	(21)	(18)	(21)	(34)	(95)
’21	(12)	(15)	(12)	(17)	(55)
’20	(8)	(7)	(5)	(9)	(30)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.90)	(1.05)	—	—	—
’25	(0.87)	(1.00)	(0.34)	(1.08)	(3.32)
’24	(0.79)	(1.02)	(1.15)	(1.01)	(3.07)
’23	(1.61)	(1.27)	(1.09)	(1.35)	(5.31)
’22	(0.98)	(1.06)	(0.86)	(1.13)	(4.05)
’21	(2.91)	(2.21)	(1.25)	(1.32)	(6.68)
’20	(2.70)	(1.80)	(1.50)	(23.07)	(31.13)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	27.00	71.40	33.00	6.60	4.67	10.44	9.47	10.93	11.40	9.90	Analyst estimates 2026–2028 Powerpack
	High	226.65	270.00	155.70	74.40	34.05	25.67	29.99	39.00	27.20	34.04
People
People	Employees	45	65	80	46	27	50	86	94	143	252
	Revenue/emp, $m	0.08	0.06	0.10	0.10	0.04	0.06	0.02	0.00	0.00	0.28
Income, $m
Income, $m	Revenue	3	4	8	4	1	3	2	0	0	71
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(17)	(27)	(33)	(42)	(111)	(79)	(130)	(238)	(270)	(343)
	EBT margin, %	(496.81)	(662.30)	(389.97)	(938.65)	(10,544.29)	(2,680.16)	(7,329.23)	(75,711.46)	(89,387.09)	(483.57)
	Net income	(17)	(27)	(33)	(42)	(111)	(79)	(130)	(238)	(270)	(343)
	Depreciation	0	0	0	0	1	1	0	(11)	(15)	(6)
Per share, $
Per share, $	Revenue	84.80	3.12	4.25	2.14	0.30	0.25	0.06	0.01	0.00	0.84
	Earnings	(421.79)	(20.69)	(16.49)	(20.09)	(31.13)	(6.68)	(4.05)	(5.31)	(3.07)	(3.32)
	Cash flow	(359.88)	(21.94)	(13.60)	(17.26)	(8.37)	(4.58)	(2.92)	(4.12)	(3.42)	(3.26)
	Capex	(6.10)	(0.19)	(0.23)	(0.04)	(0.01)	(0.02)	(0.02)	(0.02)	(0.01)	(0.01)
	Free cash flow	(365.98)	(22.14)	(13.82)	(17.30)	(8.38)	(4.60)	(2.95)	(4.14)	(3.43)	(3.26)
	Book value	367.20	30.00	26.01	7.54	33.75	15.75	12.31	9.88	9.89	8.52
	Shares, m	0	1	2	2	4	12	32	45	68	85
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.91	49.59	10.70	3.37	30.32	79.53	516.07	3,185.59	4,309.19	37.25
	P/B	0.00	5.15	1.75	0.95	0.00	4.37	3.62	4.25	2.70	4.47
	EV/Sales	(4.62)	40.71	4.44	(0.78)	(35.56)	13.40	279.45	1,732.26	2,003.95	25.73
	EV/FCF	1.07	(5.74)	(1.36)	0.10	2.30	(0.72)	(5.23)	(2.94)	(2.60)	(6.58)
Cash, $m
Cash, $m	Operating cash flow	(15)	(28)	(27)	(36)	(30)	(55)	(94)	(184)	(232)	(276)
	Capex	0	0	0	0	0	0	(1)	(1)	(1)	0
	Free cash flow	(15)	(28)	(27)	(36)	(30)	(55)	(95)	(185)	(233)	(277)
Balance, $m
Balance, $m	Working capital	17	48	59	20	119	187	398	460	691	824
	Total debt	3	10	8	4	0	1	5	20	21	50
	Net debt	(19)	(38)	(54)	(23)	(128)	(196)	(420)	(457)	(697)	(825)
	Shareholders’ equity	15	39	51	16	120	188	395	442	672	722
Returns, %
Returns, %	ROA	(91.99)	(68.66)	(55.14)	(86.87)	(137.09)	(47.42)	(40.66)	(51.37)	(43.79)	(41.73)
	ROIC	0.00	(1,673.31)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	67.26	226.53	(72.79)	(124.81)	491.96	2,308.18	(84.66)	(97.35)	(75.17)	(63.87)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SLS SELLAS Life Sciences Group, Inc.	$2.3B	— (loss-making)	— (loss-making)	−57.10% (below 0%: shrinking)	n/m	−3.52% (below 0%: shrinking)	0.00%	0.00%	Compare
CLDX Celldex Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)	Compare
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.9×	16.5×	+18.87% (above 0%: growing)	+81.25% (above 0%: growing)	+19.08% (above 0%: growing)	92.12%	48.19%	Compare
HRMY Harmony Biosciences Holdings, Inc.	$2.2B	12.2×	9.4×	+30.32% (above 0%: growing)	+88.41% (above 0%: growing)	+16.53% (above 0%: growing)	75.81%	34.18%	Compare
RXRX Recursion Pharmaceuticals, Inc.	$2.2B	— (loss-making)	— (loss-making)	−60.10% (below 0%: shrinking)	n/m	−32.03% (below 0%: shrinking)	(49.82%)	(1,759.69%)	Compare
VRDN Viridian Therapeutics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+278.67% (above 0%: growing)	n/m	−41.39% (below 0%: shrinking)	100.00%	(44,460.56%)
IRON Disc Medicine, Inc.	$2.2B	— (loss-making)	—	—	n/m	+7.83% (above 0%: growing)	0.00%	0.00%	Compare
FTRE Fortrea Holdings Inc.	$2.2B	— (loss-making)	— (loss-making)	−4.52% (below 0%: shrinking)	n/m	+53.15% (above 0%: growing)	20.52%	2.18%	Compare
NVAX Novavax, Inc.	$2.1B	— (loss-making)	— (loss-making)	−76.30% (below 0%: shrinking)	n/m	+42.95% (above 0%: growing)	74.87%	(96.84%)	Compare
Median of peers	$2.2B	—	—	−57.10%	—	+12.18%	47.70%	0.00%

All 614 Biotechnology stocks →